HARM REDUCTION FOR ALCOHOL PROBLEMS: EXPANDING TREATMENT OPTIONS. Part 2



Cite item

Full Text

Abstract

Harm reduction strategy does not see complete abstinence as the only goal of treatment. Unreadiness for immediate rejection of alcohol consumption should not be a barrier to helping to reduce the negative effects of alcohol abuse, especially in cases where the standard treatments do not produce the expected results. Such an approach is consistent with the behavioral patterns of dependence and provides more treatment options, which would otherwise not be used.

Full Text

СНИЖЕНИЯ ВРЕДА ПРИ АЛКОГОЛЬНЫХ ПРОБЛЕМАХ: РАСШИРЕНИЕ ВОЗМОЖНОСТЕЙ ЛЕЧЕНИЯ. Часть 2
×

About the authors

Mikhail L Zobin

Moscow drug addiction treatment centre

Email: dr.zobin@yandex.ru
127055, Moscow, Sushchevskaya str., 21

References

  1. Говорин Н.В., Сахаров А.В. Алкогольное бремя соматического стационара. Томск: Изд-во «Иван Федоров», 2010. 160 с
  2. Завьялов В.Ю. Необъявленная психотерапия. М.: Академический Проект, Екатерингбург: Деловая книга, 1999. 250 с
  3. Егоров А.Ю., Крупицкий Е.М., Софронов А.Г. и др. Злоупотребление алкоголем у пациентов ургентного соматического стационара / Актуальные проблемы возрастной наркологии. Мат-лы Всероссийской междисциплинарной научно-практической конф. (Челябинск 15-16 ноября 2012 г.) [Под ред. Е.Н. Кривулина, Н.А. Бохана]. Челябинск: Изд-во ПИРС, 2012. С. 119‒120
  4. Крупицкий Е.М. Краткосрочное психотерапевтическое вмешательство в наркологии с позиции доказательной медицины // Неврологический вестник. 2010. №3. С. 25‒27
  5. Менделевич В.Д. Парадоксальность принципов современной российской наркологии // Российский психиатрический журнал. 2004. №6. С. 24‒29
  6. Организация стрессопсихотерапии больных алкоголизмом в амбулаторных условиях. Методические рекомендации Минздрава СССР. М., 1984. 12 с
  7. Сиволап Ю.П. Применение антидепрессантов в наркологической практике // Обозрение психиатрии и медицинской психологии. 2010. № 2. С. 49‒51
  8. Сиволап Ю.П. О применении психотропных средств в наркологии // Наркология. 2012. № 2. С. 81‒83
  9. Чернобровкина Т.В. О кодировании в аддиктологии в вопросах и ответах // Наркология. 2008. № 1. С. 62‒82
  10. Энтин Г.М. Еще раз к вопросу стресспсихотерапии алкоголизма по методу А.Р. Довженко // Журнал невропатол. и психиатр. 1991. Т. 91, № 2. С. 132‒133
  11. Adamson S.J., Heather N., Morton V. et al. Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes // Alcohol Alcohol. 2010 Mar-Apr. Vol. 45(2). pp. 136‒142
  12. Addolorato G., Caputo F., Capristo E. et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study // Alcohol Alcohol 2002. Vol. 37. pp. 504‒508
  13. Addolorato G., Leggio L., Agabio R. et al. Baclofen: a new drug for the treatment of alcohol dependence // Int. J. Clin. Pract. 2006, Aug. Vol. 60(8). pp. 1003‒1008
  14. Addolorato G., Leggio L., Ferrulli A. et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study // Lancet. 2007. Vol. 370. pp. 1915‒1922
  15. Anton R.F., O’Malley S.S., Ciraulo D.A. et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial // JAMA 2006. Vol. 295. pp. 2003‒2017
  16. Anton R.F., Oroszi G., O’Malley S. et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study // Arch. Gen. Psychiatry. 2008. Vol. 65. pp. 135‒144
  17. Anton R.F., Pettinati H., Zweben A. et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence // J. Clin. Psychopharmacol. 2004. Vol. 24. pp. 421‒428
  18. Babor T.F., Del Boca F.K. (Eds.). Treatment matching in alcoholism. Cambridge, UK: Cambridge University Press, 2003
  19. Baser O., Chalk M., Rawson R., Gastfriend D.R. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence // Am. J. Manag Care. 2011 Jun. Vol. 17, Suppl 8. Pp. 222‒234
  20. Bouza C., Angeles M., Munoz A., Amate J.M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review // Addiction. 2004. Vol. 99. pp. 811‒828
  21. Chamorro A.J., Marcos M., Mirón-Canelo J.A. et al. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis // Addict Biol. 2012 May. Vol. 17(3). pp. 505‒512
  22. Chick J., Aschauer H., Hornik K., Investigators’ Group. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology // Drug Alcohol Depend 2004. Vol. 74(1). pp. 61‒70
  23. Cloninger C.R., Sigvardsson S., Bohman M. Type I and type II alcoholism: An update // Alcohol Health and Research World. 1996. Vol. 20. pp. 18‒23
  24. Cohen E., Feinn R., Arias A., Kranzler H.R. Alcohol treatment utilization: findings from the National Epidemiologic Survey on Alcohol and Related Conditions // Drug Alcohol Depend. 2007 Jan 12. Vol. 86(2-3). pp. 214‒221
  25. Colombo G., Agabio R., Carai M.A. et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I-Preclinical evidence // Alcohol Clin. Exp. Res. 2000. Vol. 24(1). pp. 58‒66
  26. Colombo G., Serra S., Brunetti G. et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats // Drug Alcohol Depend. 2003. Vol. 70(1). pp. 105‒108
  27. De Sousa A., De Sousa A. A one-year pragmatic trial of naltrexone vs. disulfiram in the treatment of alcohol dependence // Alcohol and Alcoholism. 2004. Vol. 39, № 6, pp. 528‒531
  28. De Sousa A., De Sousa A. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence // Alcohol and Alcoholism. 2005. Vol. 40, № 6. pp. 545‒548
  29. De Sousa A.A., De Sousa J., Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence // J. Subst Abuse Treat. 2008 Jun. Vol. 34(4). pp. 460‒463
  30. Diehl A., Ulmer L., Mutschler J. et al. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients // Alcohol Alcohol. 2010 May-Jun. Vol. 45(3). pp. 271‒277
  31. Ducci F., Goldman D. Genetic approaches to addiction: genes and alcohol // Addiction. 2008. Vol. 103. pp. 1414‒1428
  32. Dundon W., Lynch K.G., Pettinati H.M., Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy // Alcohol Clin. Exp. Res. 2004. Vol. 28(7). pp. 1065‒1073
  33. Ernst D.B., Pettinati H.M., Weiss R.D. et al. An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care // Ann Fam Med. 2008. Vol. 6. pp. 435‒440
  34. Farren C.K., Scimeca M., Wu R., Malley S.O. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence // Drug Alcohol Depend. 2009 Jan 1. Vol. 99(1-3). pp. 317‒321
  35. Fiellin D.A., Reid M.C., O’Connor P.G. New therapies for alcohol problems: application to primary care // Am. J. Med. 2000. Vol. 108(3). pp. 227‒237
  36. Finney J.W., Hahn A.C., Moos R.H. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects // Addiction. 1996. Vol. 91(12). pp. 1773‒1796
  37. Flannery B.A., Garbutt J.C., Cody M.W. et al. Baclofen for alcohol dependence: A preliminary open-label study // Alcoholism: Clinical and Experimental Research. 2004. Vol. 28. pp. 1517‒1523
  38. Fleming M.F., Mundt M.P., French M.T. et al. Brief physician advice for problem drinkers: Long-term efficacy and benefit-cost analysis // Alcoholism: Clinical and Experimental Research. 2002. Vol. 26. pp. 36‒43
  39. Freyer-Adam J., Coder B., Baumeister S.E. et al. Brief alcohol intervention for general hospital inpatients: a randomized controlled trial // Drug Alcohol Depend. 2008 Mar 1. Vol. 93(3). pp. 233‒243
  40. Garbutt J.C., Kampov-Polevoy A.B., Gallop R. et al. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial // Alcohol Clin. Exp. Res. 2010 Nov. Vol. 34(11). pp. 1849‒1857
  41. Garbutt J.C., Kranzler H.R., O’Malley S.S. et al. Efficacy and tolerability of long- acting injectable Naltrexone for alcohol dependence: A randomized controlled trial // Journal of the American Medical Association. 2005. Vol. 293. pp. 1617‒1625
  42. Garcia F., Moral R., de Torres P. et al. Effectiveness of medical counseling for alcoholic patients and patients with excessive alcohol consumption seen in primary care. [Article in Spanish] // Atencion Primaria. 2003. Vol. 31. pp. 146‒154
  43. Harris B.R., Prendergast M.A., Gibson D.A. et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors // Alcohol Clin. Exp. Res. 2002. Vol. 26 (12). pp. 1779‒1793
  44. Heather N., Adamson S.J., Raistrick D. et al. Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups // Alcohol Alcohol. 2010 Mar-Apr. Vol. 45(2). pp. 128‒135
  45. Hodgins D. Can patients with alcohol use disorders return to social drinking? Yes, so what should we do about it? // Canadian Journal of Psychiatry. 2005. Vol. 50. pp. 264‒265
  46. Hodgins D., Leigh G., Milne R., Gerrish R. Drinking goal selection in behavioral self-management treatment of chronic alcoholics // Addictive Behaviors. 1997. Vol. 22. pp. 247‒255
  47. Hungerford D.W., Pollock D.A. Emergency department services for patients with alcohol problems: Research directions // Academic Emergency Medicine. 2003. Vol. 10. pp. 79‒84
  48. Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academy Press, 2006
  49. Johnson B.A. Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study // Alcohol Clin. Exp. Res. 2004. Vol. 28. pp. 1137–1144
  50. Johnson B.A. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment // CNS Drugs. 2004. Vol. 18(15). pp. 1105‒1118
  51. Johnson B.A., Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients // Curr Pharm Des. 2010. Vol. 16(19). pp. 2103‒2112
  52. Johnson B.A, Ait-Daoud N., Seneviratne C. et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking // Am. J. Psychiatry. 2011. Vol. 168(3). pp. 265‒275
  53. Johnson B.A., Roache J.D., Javors M.A. et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial // J.A.M.A. 2000. Vol. 284(8). pp. 963‒971
  54. Johnson B.A., Rosenthal N., Capece J.A. et al. Topiramate for treating alcohol dependence: a randomized controlled trial // J.A.M.A. 2007. Vol. 298. pp. 1641‒1651
  55. Jonas D.E., Garbutt J.C., Amick H.R. et al. Behavioral Counseling After Screening for Alcohol Misuse in Primary Care: A Systematic Review and Meta-analysis for the U.S. Preventive Services Task Force // Ann. Intern Med. 2012 Sep 25. doi: 10.7326/0003-4819-157-9-201211060-00544
  56. Kaner E.F., Dickinson H.O., Beyer F., Pienaar E., Schlesinger C., Campbell F. et al. The effectiveness of brief alcohol interventions in primary care settings: a systematic review // Drug Alcohol Rev. 2009. Vol. 28. pp. 301–23
  57. Kenna G.A. Medications acting on the serotonergic system for the treatment of alcohol dependent patients // Curr Pharm Des. 2010. Vol. 16(19). pp. 2126‒2135
  58. Kenna G.A., Lomastro T.L., Schiesl A., Leggio L., Swift R.M. Review of topiramate: an antiepileptic for the treatment of alcohol dependence // Curr Drug Abuse Rev. 2009 May. Vol. 2(2). pp. 135‒142
  59. Kranzler H.R., Burleson J.A., Brown J., Babor T.F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics // Alcohol Clin. Exp. Res. 1996. Vol. 20(9). pp. 1534‒1541
  60. Kranzler H.R., Pierucci-Lagha A., Feinn R., Hernandez-Avila C. Effects of ondansetron in early-versus late-onset alcoholics: a prospective, open-label study // Alcohol Clin. Exp. Res. 2003. Vol. 27(7). pp. 1150‒1155
  61. Laaksonen E., Koski-Jannes A., Salaspuro M. et al. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence // Alcohol Alcohol. 2008. Vol. 43. pp. 53‒61
  62. Lesch O.M., Walter H. Subtypes of alcoholism and their role in therapy // Alcohol Alcohol Suppl. 1996 Mar. Vol. 1. pp. 63‒67. Review
  63. Lovinger D.M. Serotonin’s role in alcohol’s effects on the brain // Alcohol Health Res World. 1997. Vol. 21(2). pp. 114‒120. Review
  64. Ma J.Z., Ait-Daoud N., Johnson B.A. Topiramate reduces the harm of excessive drinking: implications for public health and primary care // Addiction. 2006. Vol. 101(11). pp. 1561‒1568
  65. Mann K., Lehert P., Morgan M.Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis // Alcohol Clin Exp Res. 2004. Vol. 28. pp. 51‒63
  66. Martensen-Larsen O. Five years’ experience with disulfiram in the treatment of alcoholics // Quarterly Journal of Studies on Alcohol. 1953. Vol. 14, № 3. pp. 406‒418
  67. Mason B.J., Goodman A.M., Chabac S., Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation // J. Psychiatr Res. 2006. Vol. 40. pp. 383‒393
  68. Mason B.J., Salvato F.R., Williams L.D. et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence // Arch Gen Psychiatry. 1999 Aug. Vol. 56(8). pp. 719‒724
  69. McQueen J., Howe T.E., Allan L., Mains D., Hardy V. Brief interventions for heavy alcohol users admitted to general hospital wards. Cochrane Database of Systematic Reviews 2011, Issue 8. Art. No.: CD005191. doi: 10.1002/14651858.CD005191.pub3
  70. Morley K.C., Teesson M., Reid S.C. et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial // Addiction. 2006. Vol. 101. pp. 1451‒1462
  71. Moss H.B., Chen C.M., Yi H.Y. Subtypes of alcohol dependence in a nationally representative sample // Drug Alcohol Depend. 2007 Dec 1. Vol. 91(2-3). pp. 149‒158
  72. Moss H.B., Chen C.M., Yi H.Y. Prospective follow-up of empirically derived Alcohol Dependence subtypes in wave 2 of the National Epidemiologic Survey on Alcohol And Related Conditions (NESARC): recovery status, alcohol use disorders and diagnostic criteria, alcohol consumption behavior, health status, and treatment seeking // Alcohol Clin Exp Res. 2010 Jun. Vol. 34(6). pp. 1073‒1083
  73. Muckle W., Muckle J., Welch V., Tugwell P. Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD006747. doi: 10.1002/14651858.CD006747.pub2
  74. Muzyk A.J., Rivelli S.K., Gagliardi J.P. Defining the role of baclofen for the treatment of alcohol dependence: a systematic review of the evidence // CNS Drugs. 2012 Jan 1. Vol. 26(1). pp. 69‒78
  75. Nunes E.V., Levin F.R. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis // JAMA 2004. Vol. 291(15). pp. 1887‒1896
  76. Olmsted C.L., Kockler D.R. Topiramate for alcohol dependence // Ann. Pharmacother. 2008 Oct. Vol. 42(10). pp. 1475‒1480
  77. Oslin D.W., Berrettini W., Kranzler H.R. et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients // Neuropsychopharmacology. 2003. Vol. 28. pp. 1546‒1542
  78. Pascoe J.E., Williams K.L., Mukhopadhyay P. et al. Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys // Psychoneuroendocrinology. 2008 May. Vol. 33(4). pp. 478-486
  79. Pettinati H.M., O’Brien C.P., Rabinowitz A.R. et al. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking // J. Clin. Psychopharmacol. 2006 Dec. Vol. 26(6). pp. 610‒625
  80. Pettinati H.M., Silverman B.L., Battisti J.J. et al. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence // Alcohol Clin. Exp. Res. 2011 Oct. Vol. 35(10). pp. 1804‒1811
  81. Pettinati H.M., Volpicelli J.R., Kranzler H.R. et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype // Alcohol Clin Exp Res. 2000. Vol. 24(7). pp. 1041‒1049
  82. Pettinati H.M., Weiss R.D., Miller W.R. et al. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. COMBINE Monograph Series, Volume 2 (DHHS Publication No. 04-5289), National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 2004
  83. Richardson K., Baillie A., Reid S. et al. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol? // Addiction. 2008 Jun. Vol. 103(6). pp. 953‒959
  84. Rösner S., Hackl-Herrwerth A., Leucht S. et al. Acamprosate for alcohol dependence. Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD004332. doi: 10.1002/14651858.CD004332.pub2
  85. Rösner S., Hackl-Herrwerth A., Leucht S. et al. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No.: CD001867. doi: 10.1002/14651858.CD001867. pub3
  86. Rösner S., Leucht S., Lehert P., Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes // J. Psychopharmacol. 2008 Jan. Vol. 22(1). pp. 11‒23
  87. Saitz R. Alcohol screening and brief intervention in primary care: Absence of evidence for efficacy in people with dependence or very heavy drinking // Drug Alcohol Rev. 2010 Nov. Vol. 29(6). pp. 631‒640
  88. Sass H., Soyka M., Mann K., Zieglgansberger W. Relapse prevention by acamprosate: Results from a placebo-controlled study on alcohol dependence // Archives of General Psychiatry. 1996. Vol. 53. pp. 673‒680
  89. Schmidt L., Room R. Cross-cultural applicability in international classifications and research on alcohol dependence // Journal of Studies on Alcohol. 1999. Vol. 60. pp. 448‒462
  90. Sellers E.M., Toneatto T., Romach M.K. et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence // Alcohol Clin. Exp. Res. 1994. Vol. 18(4). pp. 879‒885
  91. Skradski S., White H.S. Topiramate blocks kainate-evoked cobalt influx into cultured neurons // Epilepsia. 2000. Vol. 41, Suppl 1. рp. 45‒47
  92. Srisurapanont M., Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005; CD001867
  93. Streeton C., Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials // Alcohol and Alcoholism. 2001. Vol. 36. pp. 544‒552
  94. Suh J.J., Pettinati H.M., Kampman K.M., O’Brien C.P. The status of disulfiram: a half of a century later //Journal of Clinical Psychopharmacology. 2006. Vol. 26, № 3. pp. 290‒302
  95. Swift R., Pettinati H.M. Choosing pharmacotherapies for the COMBINE study‒process and procedures: An investigational approach to combination pharmacotherapy for the treatment of alcohol dependence // Journal of Studies on Alcohol. 2005. Vol. 66(Suppl. 15). pp. 141‒147
  96. Torrens M., Fonseca F., Mateu G., Farré M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis // Drug Alcohol Depend 2005. Vol. 78(1). pp. 1‒22
  97. US Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: recommendation statement // Ann Intern Med. 2004. Vol. 140. pp. 554‒556
  98. Walters G.D. The heritability of alcohol abuse and dependence: A meta-analysis of behavior genetic research // Am J. Drug Alcohol Abuse. 2002. Vol. 28. pp. 557‒584
  99. Weiss R.D., O’Malley S.S., Hosking J.D. et al. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study // J. Stud Alcohol Drugs. 2008. Vol. 69(6). pp. 878‒884
  100. White H.S., Brown S.D., Woodhead J.H. et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism // Epilepsia. 2000. Vol. 41, Suppl 1. pp. 17‒20
  101. Williams K.L., Broadbear J.H., Woods J.H. Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys // Alcohol Clin. Exp. Res. 2004. Vol. 28. pp. 566‒171

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Zobin M.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies